Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Cue Biopharma Inc (NASDAQ: CUE) closed the day trading at $0.25 down -5.44% from the previous closing price of $0.27. In other words, the price has decreased by -$5.44 from its previous closing price. On the day, 1.92 million shares were traded. CUE stock price reached its highest trading level at $0.273 during the session, while it also had its lowest trading level at $0.2409.
Ratios:
For a better understanding of CUE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.66 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.47 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on March 13, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On November 21, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 21, 2022, with a $7 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CUE now has a Market Capitalization of 19967890 and an Enterprise Value of 5721890. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.81 while its Price-to-Book (P/B) ratio in mrq is 1.49. Its current Enterprise Value per Revenue stands at 0.806 whereas that against EBITDA is -0.152.
Stock Price History:
The Beta on a monthly basis for CUE is 1.49, which has changed by -0.7346535 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, CUE has reached a high of $1.75, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -59.44%, while the 200-Day Moving Average is calculated to be -65.58%.
Shares Statistics:
Over the past 3-months, CUE traded about 401.24K shares per day on average, while over the past 10 days, CUE traded about 964800 shares per day. A total of 78.74M shares are outstanding, with a floating share count of 78.36M. Insiders hold about 0.49% of the company’s shares, while institutions hold 24.21% stake in the company. Shares short for CUE as of 1764288000 were 441825 with a Short Ratio of 1.10, compared to 1761868800 on 365072. Therefore, it implies a Short% of Shares Outstanding of 441825 and a Short% of Float of 0.5599999999999999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Cue Biopharma Inc (CUE).The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.11 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.41 and -$0.41 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.48, with 1.0 analysts recommending between -$0.48 and -$0.48.
Revenue Estimates
2 analysts predict $1.75M in revenue for. The current quarter. It ranges from a high estimate of $2.5M to a low estimate of $1M. As of. The current estimate, Cue Biopharma Inc’s year-ago sales were $1.58MFor the next quarter, 2 analysts are estimating revenue of $2.5M. There is a high estimate of $2.5M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 2 analysts have provided revenue estimates for CUE’s current fiscal year. The highest revenue estimate was $8M, while the lowest revenue estimate was $6.5M, resulting in an average revenue estimate of $7.25M. In the same quarter a year ago, actual revenue was $9.29MBased on 2 analysts’ estimates, the company’s revenue will be $5.5M in the next fiscal year. The high estimate is $10M and the low estimate is $1M.
